IN2014DN06104A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN06104A IN2014DN06104A IN6104DEN2014A IN2014DN06104A IN 2014DN06104 A IN2014DN06104 A IN 2014DN06104A IN 6104DEN2014 A IN6104DEN2014 A IN 6104DEN2014A IN 2014DN06104 A IN2014DN06104 A IN 2014DN06104A
- Authority
- IN
- India
- Prior art keywords
- compounds
- terms
- therapeutic uses
- inventions relates
- inventions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The inventions relates to compounds of (I) and therapeutic uses thereof : (I) The terms Z Y and R are as defined in the claims.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1201566.5A GB201201566D0 (en) | 2012-01-30 | 2012-01-30 | New chemical compounds |
| PCT/GB2013/050212 WO2013114113A1 (en) | 2012-01-30 | 2013-01-30 | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06104A true IN2014DN06104A (en) | 2015-08-14 |
Family
ID=45876325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6104DEN2014 IN2014DN06104A (en) | 2012-01-30 | 2013-01-30 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10000481B2 (en) |
| EP (1) | EP2809670B1 (en) |
| JP (1) | JP6199316B2 (en) |
| CN (4) | CN104203948A (en) |
| AU (1) | AU2013213954B2 (en) |
| BR (1) | BR112014018795B1 (en) |
| CA (1) | CA2862940C (en) |
| DK (1) | DK2809670T3 (en) |
| EA (1) | EA026657B1 (en) |
| ES (1) | ES2637340T3 (en) |
| GB (1) | GB201201566D0 (en) |
| HK (1) | HK1200447A1 (en) |
| HU (1) | HUE035332T2 (en) |
| IL (1) | IL233595B (en) |
| IN (1) | IN2014DN06104A (en) |
| MX (1) | MX352927B (en) |
| NZ (1) | NZ627361A (en) |
| PL (1) | PL2809670T3 (en) |
| PT (1) | PT2809670T (en) |
| WO (1) | WO2013114113A1 (en) |
| ZA (1) | ZA201405070B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201201566D0 (en) | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| RU2635359C2 (en) * | 2012-04-23 | 2017-11-13 | Дженентек Инк. | Intermediate chemical compounds and methods for producing compounds |
| WO2015027092A1 (en) | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Process for preparing a compound |
| CN104829609B (en) * | 2014-02-11 | 2016-08-03 | 北大方正集团有限公司 | Substituted Pyridopyrimidine compound and its preparation method and application |
| MA41559A (en) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | CONDENSED PYRIMIDINE COMPOUND OR A SALT THEREOF |
| US10032914B2 (en) * | 2015-10-20 | 2018-07-24 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor device and manufacturing method thereof |
| CA3015484C (en) | 2016-02-23 | 2022-11-08 | Taiho Pharmaceutical Co., Ltd. | Novel condensed pyrimidine compound or salt thereof |
| TWI862480B (en) | 2017-08-21 | 2024-11-21 | 日商大鵬藥品工業股份有限公司 | Fusion protein of DCTN1 protein and RET protein |
| TW202043198A (en) | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | Compounds and compositions for treating conditions associated with sting activity |
| CN111518096B (en) | 2019-02-02 | 2022-02-11 | 江苏威凯尔医药科技有限公司 | Two-faced God kinase JAK family inhibitor and its preparation and application |
| EP4007757B1 (en) | 2019-08-01 | 2025-09-10 | Sperogenix Therapeutics Limited | Heterocyclic compounds as kinase inhibitor and uses thereof |
| IT202000005527A1 (en) * | 2020-03-16 | 2021-09-16 | Univ Degli Studi Di Trento | Therapeutic treatment of chromatinopathies |
| JP2023540674A (en) * | 2020-07-15 | 2023-09-26 | アイエフエム デュー インコーポレイテッド | Compounds and compositions for treating conditions associated with STING activity |
| TW202216685A (en) * | 2020-07-15 | 2022-05-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | Compounds and compositions for treating conditions associated with sting activity |
| CN116157394A (en) | 2020-07-15 | 2023-05-23 | 艾福姆德尤股份有限公司 | Compounds and compositions for the treatment of diseases associated with STING activity |
| TW202235073A (en) | 2021-01-08 | 2022-09-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | Compounds and compositions for treating conditions associated with sting activity |
| US12503436B2 (en) | 2021-08-10 | 2025-12-23 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with STING activity |
| US20230250060A1 (en) * | 2022-01-12 | 2023-08-10 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN116554170A (en) * | 2023-04-26 | 2023-08-08 | 上海大学 | The preparation method of 4-fluoro-7-azaindole |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1012976A (en) * | 1909-03-25 | 1911-12-26 | Adolf Bordt | Adding-machine. |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| US20050130954A1 (en) * | 2003-11-21 | 2005-06-16 | Mitchell Ian S. | AKT protein kinase inhibitors |
| CA2711614A1 (en) * | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| WO2009093012A1 (en) * | 2008-01-22 | 2009-07-30 | Vernalis (R & D) Ltd | Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| AR071717A1 (en) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | PIRROLO [2,3-B] CHK1 AND CHK2 QUINASE INHIBITING PIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME IN THE TREATMENT AND PREVENTION OF CANCER. |
| KR101764556B1 (en) * | 2008-06-11 | 2017-08-02 | 제넨테크, 인크. | Diazacarbazoles and methods of use |
| CN102573994B (en) * | 2009-08-06 | 2015-06-24 | 默克专利有限公司 | Novel bicyclic urea compounds |
| WO2011146313A1 (en) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
-
2012
- 2012-01-30 GB GBGB1201566.5A patent/GB201201566D0/en not_active Ceased
-
2013
- 2013-01-30 HK HK15100794.1A patent/HK1200447A1/en unknown
- 2013-01-30 ES ES13703121.7T patent/ES2637340T3/en active Active
- 2013-01-30 DK DK13703121.7T patent/DK2809670T3/en active
- 2013-01-30 CN CN201380014717.5A patent/CN104203948A/en active Pending
- 2013-01-30 MX MX2014009112A patent/MX352927B/en active IP Right Grant
- 2013-01-30 US US14/375,353 patent/US10000481B2/en active Active
- 2013-01-30 WO PCT/GB2013/050212 patent/WO2013114113A1/en not_active Ceased
- 2013-01-30 JP JP2014555310A patent/JP6199316B2/en not_active Expired - Fee Related
- 2013-01-30 CN CN201610920724.7A patent/CN107011341A/en active Pending
- 2013-01-30 EA EA201491376A patent/EA026657B1/en not_active IP Right Cessation
- 2013-01-30 PL PL13703121T patent/PL2809670T3/en unknown
- 2013-01-30 EP EP13703121.7A patent/EP2809670B1/en active Active
- 2013-01-30 PT PT137031217T patent/PT2809670T/en unknown
- 2013-01-30 BR BR112014018795-9A patent/BR112014018795B1/en not_active IP Right Cessation
- 2013-01-30 CA CA2862940A patent/CA2862940C/en active Active
- 2013-01-30 IN IN6104DEN2014 patent/IN2014DN06104A/en unknown
- 2013-01-30 AU AU2013213954A patent/AU2013213954B2/en active Active
- 2013-01-30 HU HUE13703121A patent/HUE035332T2/en unknown
- 2013-01-30 NZ NZ627361A patent/NZ627361A/en not_active IP Right Cessation
- 2013-01-30 CN CN202010405942.3A patent/CN111484493A/en active Pending
- 2013-01-30 CN CN201610920720.9A patent/CN106866658B/en not_active Expired - Fee Related
-
2014
- 2014-07-10 IL IL233595A patent/IL233595B/en active IP Right Grant
- 2014-07-11 ZA ZA2014/05070A patent/ZA201405070B/en unknown
-
2018
- 2018-06-15 US US16/009,439 patent/US10889582B2/en active Active
-
2020
- 2020-11-30 US US17/107,176 patent/US20210206762A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06104A (en) | ||
| MY185016A (en) | Progenitor cells of mesodermal lineage | |
| GB201106743D0 (en) | Novel compounds | |
| MX2013005549A (en) | Heterocycle amines and uses thereof. | |
| GEP20186816B (en) | Anty il-36r antybodies | |
| IL238476A0 (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| GB201106750D0 (en) | Novel compounds | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| MX2015006324A (en) | Methods for the manufacture of proteolytically processed polypeptides. | |
| PH12015501083B1 (en) | Novel pyridine derivatives | |
| MY179412A (en) | Pyridine-2-amides useful as cb2 agonists | |
| MX2014012477A (en) | Pyrrolopyrazone inhibitors of tankyrase. | |
| MY182328A (en) | Pyridine-2-amides useful as cb2 agonists | |
| TWD158887S (en) | Compact | |
| EP4582090A3 (en) | Composition comprising pegylated arginine deiminase | |
| IN2014DN03298A (en) | ||
| MX349373B (en) | Novel pyrazine derivatives. | |
| TR201903918T4 (en) | Compositions containing a dispersing agent and their preparation. | |
| MX2012010127A (en) | Derivatives of aminoindanes, their preparation and their application in therapeutics. | |
| IN2015DN00085A (en) | ||
| UA117567C2 (en) | Galactagogue compositions based on phosphatidylserine | |
| MX365192B (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy. | |
| IN2015DN00962A (en) | ||
| MX351093B (en) | Novel azetidine derivatives. | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier |